Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3598)
All Articles published online
|
Feb 28, 2005 (publication date) through Jan 31, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang XS, Sheng Z, Ruan YB, Guang Y, Yang ML. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol 2005; 11(8): 1220-1224 [PMID: 15754409 DOI: 10.3748/wjg.v11.i8.1220] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i8/1220.htm |
| Number | Citing Articles |
| 1 |
Yu-Chen Chuang, Jen-Chih Tseng, Li-Rung Huang, Chun-Ming Huang, Chi-Ying F. Huang, Tsung-Hsien Chuang. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.01075
|
| 2 |
Marion Jurk, Jörg Vollmer. Therapeutic Applications of Synthetic CpG Oligodeoxynucleotides as TLR9 Agonists for Immune Modulation. BioDrugs 2007; 21(6): 387 doi: 10.2165/00063030-200721060-00006
|
| 3 |
Arthur M. Krieg. Development of TLR9 agonists for cancer therapy. Journal of Clinical Investigation 2007; 117(5): 1184 doi: 10.1172/JCI31414
|
| 4 |
Srdjan Novaković, Vida Stegel, Andreja Kopitar, Alojz Ihan, Barbara Jezeršek Novaković. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs. Vaccine 2007; 25(49): 8241 doi: 10.1016/j.vaccine.2007.09.067
|
| 5 |
Tianqi Wang, Yusuke Suita, Saradha Miriyala, Jordan Dean, Nikos Tapinos, Jie Shen. Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. Pharmaceutics 2021; 13(4): 520 doi: 10.3390/pharmaceutics13040520
|
| 6 |
Su‐Mi Bae, Yong‐Wan Kim, Sun‐Young Kwak, Yong‐Wook Kim, Duck‐Yeong Ro, Jong‐Chul Shin, Choong‐Hak Park, Sei‐Jun Han, Chung‐Hun Oh, Chong‐Kook Kim, Woong‐Shick Ahn. Photodynamic therapy‐generated tumor cell lysates with CpG‐oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells. Cancer Science 2007; 98(5): 747 doi: 10.1111/j.1349-7006.2007.00447.x
|
| 7 |
Misha D. Luyer, Wim A. Buurman, M'hamed Hadfoune, T Wolfs, Cornelis van't Veer, Jan A. Jacobs, Cornelis H. Dejong, Jan Willem M. Greve. Exposure to Bacterial DNA Before Hemorrhagic Shock Strongly Aggravates Systemic Inflammation and Gut Barrier Loss via an IFN-γ-Dependent Route. Annals of Surgery 2007; 245(5): 795 doi: 10.1097/01.sla.0000251513.59983.3b
|
| 8 |
Arthur Krieg, Julie Himes. Nucleic Acids in Innate Immunity. 2008; : 129 doi: 10.1201/9781420068269.ch10
|
| 9 |
Kouji Maruyama, Zohair Selmani, Hidee Ishii, Ken Yamaguchi. Innate immunity and cancer therapy. International Immunopharmacology 2011; 11(3): 350 doi: 10.1016/j.intimp.2010.09.012
|
| 10 |
Michael J. McCluskie, Risini D. Weeratna. Immunopotentiators in Modern Vaccines. 2006; : 73 doi: 10.1016/B978-012088403-2/50006-X
|
| 11 |
Risini D. Weeratna, Heather L. Davis, Liana Medynski, Arthur M. Krieg. Potential use of CpG ODN for cancer immunotherapy. Update on Cancer Therapeutics 2006; 1(1): 49 doi: 10.1016/j.uct.2006.04.002
|
| 12 |
Deyu Zhang, Shitai Zhang, Zheng He, Ying Chen. Cytosine–phosphate–guanine oligodeoxynucleotides alleviate radiation-induced kidney injury in cervical cancer by inhibiting DNA damage and oxidative stress through blockade of PARP1/XRCC1 axis. Journal of Translational Medicine 2023; 21(1) doi: 10.1186/s12967-023-04548-y
|
| 13 |
S. Arab, M. Mojarrad, M. Motamedi, R. Mirzaei, M. H. Modarressi, J. Hadjati. Tumour Regression Induced by Co‐administration of MIP‐3α and CpG in an Experimental Model of Colon Carcinoma. Scandinavian Journal of Immunology 2013; 78(1): 28 doi: 10.1111/sji.12058
|
| 14 |
Yanal M Murad, Timothy M Clay, H Kim Lyerly, Michael A Morse. CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy. Expert Opinion on Biological Therapy 2007; 7(8): 1257 doi: 10.1517/14712598.7.8.1257
|
| 15 |
Yanal M. Murad, Timothy M. Clay. CpG Oligodeoxyneucleotides as TLR9 Agonists. BioDrugs 2009; 23(6): 361 doi: 10.2165/11316930-000000000-00000
|
| 16 |
Arthur M. Krieg. Therapeutic potential of Toll-like receptor 9 activation. Nature Reviews Drug Discovery 2006; 5(6): 471 doi: 10.1038/nrd2059
|
| 17 |
Jörg Vollmer, Arthur M. Krieg. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Advanced Drug Delivery Reviews 2009; 61(3): 195 doi: 10.1016/j.addr.2008.12.008
|
| 18 |
Carole Bourquin, Susanne Schreiber, Sebastian Beck, Gunther Hartmann, Stefan Endres. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. International Journal of Cancer 2006; 118(11): 2790 doi: 10.1002/ijc.21681
|
| 19 |
Margaret A. McBride, Allison M. Owen, Cody L. Stothers, Antonio Hernandez, Liming Luan, Katherine R. Burelbach, Tazeen K. Patil, Julia K. Bohannon, Edward R. Sherwood, Naeem K. Patil. The Metabolic Basis of Immune Dysfunction Following Sepsis and Trauma. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.01043
|
| 20 |
Christian Manegold, Donald Gravenor, Donald Woytowitz, Jörg Mezger, Vera Hirsh, Gary Albert, Mohammed Al-Adhami, David Readett, Arthur M. Krieg, Cynthia Gail Leichman. Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 2008; 26(24): 3979 doi: 10.1200/JCO.2007.12.5807
|
| 21 |
Udo Holtick, Max E Scheulen, Michael S von Bergwelt-Baildon, Martin R Weihrauch. Toll-like receptor 9 agonists as cancer therapeutics. Expert Opinion on Investigational Drugs 2011; 20(3): 361 doi: 10.1517/13543784.2011.553187
|
| 22 |
Sheng-ran Liang, Guang-rui Hu, Li-juan Fang, Su-jing Huang, Jin-song Li, Ming-yi Zhao, Min-jie Meng. CpG oligodeoxynucleotides enhance chemosensitivity of 5-fluorouracil in HepG2 human hepatoma cells via downregulation of the antiapoptotic factors survivin and livin. Cancer Cell International 2013; 13(1) doi: 10.1186/1475-2867-13-106
|
| 23 |
Yukari Kuramoto, Shigeru Kawakami, Shuwen Zhou, Kyouichi Fukuda, Fumiyoshi Yamashita, Mitsuru Hashida. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. Journal of Controlled Release 2008; 126(3): 274 doi: 10.1016/j.jconrel.2007.12.007
|
| 24 |
Jing Wang, Yuko Shirota, Defne Bayik, Hidekazu Shirota, Debra Tross, James L. Gulley, Lauren V. Wood, Jay A. Berzofsky, Dennis M. Klinman. Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells. The Journal of Immunology 2015; 194(9): 4215 doi: 10.4049/jimmunol.1402004
|
| 25 |
Amy Gillgrass, Ali Ashkar. Stimulating natural killer cells to protect against cancer: recent developments. Expert Review of Clinical Immunology 2011; 7(3): 367 doi: 10.1586/eci.10.102
|
| 26 |
Ekaterina A Alyamkina, Evgenia V Dolgova, Anastasia S Likhacheva, Vladimir A Rogachev, Tamara E Sebeleva, Valeriy P Nikolin, Nelly A Popova, Konstantin E Orishchenko, Dmitriy N Strunkin, Elena R Chernykh, Stanislav N Zagrebelniy, Sergei S Bogachev, Mikhail A Shurdov. Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice. Genetic Vaccines and Therapy 2009; 7(1) doi: 10.1186/1479-0556-7-12
|